Introduction: Imidapril is an angiotensin converting enzyme inhibitor (ACEI) that is
adverse effects of decreasing glomerular filtration rate (GFR) and causing hyperkalemia, there are very few clinical data on the long-term effect of imidapril on glomerular function. We conducted a retrospective cohort study using a clinical database to evaluate and compare the long-term effects of imidapril and amlodipine on renal parameters in Japanese hypertensive patients in routine clinical practice. Methods: We identified cohorts of new users of imidapril (n = 57) and a propensity score-matched group with an equal number of new users of amlodipine (n = 57). We used a multivariable regression model to evaluate and compare the effects of the drugs on laboratory parameters including serum levels of creatinine, potassium, sodium, blood urea nitrogen, and estimated GFR (eGFR) between imidapril users and amlodipine users up to 12 months after the initiation of study drug administration. The mean exposure of imidapril and amlodipine was 226.2 and 235.2 days, respectively. Results: We found a significant increase of serum creatinine and potassium levels and a decrease of eGFR in imidapril users from the baseline period to the exposure period. The reduction of eGFR and the increase of serum creatinine and potassium levels in imidapril
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INTRODUCTION
Angiotensin converting enzyme inhibitors (ACEIs) are one of the most frequently used type of antihypertensive drugs. Recent clinical trials reported that ACEIs improve microalbuminuria and prevent the progression of diabetic nephropathy [1] [2] [3] [4] . On the other hand, the use of ACEIs may also be associated with the syndrome of ''functional renal sufficiency'' and hyperkalemia [5] . Therefore, various guidelines recommend that patients treated with ACEIs should be monitored for decreased glomerular filtration rate (GFR) and hyperkalemia, especially those with chronic kidney disease (CKD) [6] [7] [8] .
Imidapril is an ACEI that is used in the treatment of essential hypertension, renal parenchymal hypertension, and diabetic nephropathy associated with type 1 diabetes mellitus (DM) in Japan [1] . 
METHODS

Data Source
This study was a retrospective cohort study using a clinical database. We used data from the Nihon University School of Medicine (NUSM) [18] .
Data Elements
For each patient, we collected information on patient demographics (age and sex), medical history, and use of medication as baseline covariates for adjustment. Medical history included cerebrovascular disease (ICD-10 code; I60-69), ischemic heart disease (I20-I25), other heart disease (I30-I52), malignant neoplasm (C00-C97), liver disease (K70-K77), kidney 
Statistical Analysis
All statistical analyses were performed using SAS software, version 9.3 (SAS Institute Inc., Cary, NC, USA). This study was a retrospective observational study, and because the non-randomized subjects had inherent issues of selection bias and confounding factors, we used a propensity score method to minimize selection bias and a multivariable regression model to measure the effect of imidapril and amlodipine on blood test results while controlling for baseline confounders. We used propensity score matching (greedy 1:1 matching) to reduce bias by balancing covariates between settings. The details of the propensity score method are described elsewhere [19] [20] [21] [22] . In brief, the propensity score for each subject was obtained by fitting a logistic regression model that included the predictor variable as an outcome and all the baseline covariates in Table 1 . After the propensity score was constructed, we matched the propensity score of each user of imidapril and amlodipine. A nearest-neighbor-matching algorithm with a ''greedy'' heuristic was used to match patients and the logit of their propensity score [23] . After propensity score matching, we used t test for continuous variables and Chi-squared test for categorical data to Table 1 shows the baseline characteristics of patients who had been treated with imidapril and amlodipine, before and after propensity score matching. After propensity score matching, there was no statistically difference in baseline characteristics between imidapril and amlodipine users. The mean age was 61.2 and 63.2 years, and 50.9% and 47.4% of imidapril and amlodipine users were female, respectively. In imidapril users and amlodipine users, 7.0% and 8.8% were currently using a b-blocker, and 7.0% and 8.8% were using an a ? b-blocker, respectively. Table 2 shows the antihypertensive drugs used during the exposure period. There was no significant difference in use of any other antihypertensive drugs between imidapril and amlodipine users. Table 3 shows baseline laboratory parameters after propensity score matching. There was no significant difference in any laboratory parameter, including serum creatinine, potassium, and sodium, BUN, and eGFR, between imidapril and amlodipine users. Table 4 shows laboratory parameters at baseline and during the exposure period. In imidapril users, serum creatinine and potassium levels were significantly increased, and eGFR was significantly decreased during the exposure period compared with the baseline period. BUN and sodium level did not significantly change during the exposure period compared with the baseline period in imidapril users. In amlodipine users, there was no significant change in any laboratory parameter during the exposure period compared with the baseline period. Table 5 shows the mean changes in laboratory parameters during the exposure period from the baseline period. The increase 
RESULTS
DISCUSSION
In this study, we evaluated and compared the effect of imidapril and amlodipine on renal parameters including serum creatinine level and eGFR in a long-term administration period up to 12 months. We found a significant increase of serum creatinine and potassium level, and a significant decrease of eGFR from the baseline period to during the exposure period in imidapril users. The increase of serum creatinine and potassium level and reduction of eGFR were significantly greater in imidapril users compared with amlodipine users. These results suggest that imidapril has a slightly unfavorable effect on renal function and electrolyte balance compared with amlodipine.
It is well known that treatment with ACEIs reduces GFR through a vasodilator effect on the efferent arteriole [7] . Acute renal failure is likely to occur especially in patients with renal hypoperfusion, including those with high-grade bilateral renal artery stenosis, because angiotensin II is necessary for maintenance of GFR during states of significant volume depletion [5] . Therefore, various guidelines recommend that patients treated with ACEIs should be monitored for a decrease in GFR, especially patients with CKD [6] [7] [8] . Our findings, showing the effects of imidapril treatment, to increase serum creatinine level and decrease eGFR, support these guidelines. Also, hyperkalemia is a common adverse effect with the use of ACEIs [6] . Supporting this, our findings showed an increase in the level of serum potassium in imidapril users. Considering these results, regular checks of GFR and potassium level are needed in users of imidapril, as well as other ACEIs, at least for 1 year after its initiation.
However, an increase in creatinine level or a decrease in eGFR may not be of clinical concern and does not always require a reduction in dose or discontinuation, because the mean levels of creatinine and eGFR in this study were within the normal range during the study period in both drug users. In addition, Apperloo et al.
suggested that the therapy-induced GFR decline is of hemodynamic and not of structural origin, and this initial GFR decline is associated with subsequent stable renal function [24] . Maschio et al. reported that the serum creatinine concentration in the ACEI, benazepril, group increased more markedly than that in the placebo group during the first 2 months of administration. However, the speed of the increase in creatinine slowed after 2 months, and the serum concentration of creatinine in the benazepril group was lower than that in the placebo group at 12, 24, and 36 months.
Meanwhile, urinary protein decreased after 2 months of treatment, and the progression of renal insufficiency was prevented, including the need for dialysis or doubling of the baseline serum creatinine concentration [25] . Similarly to previous reports, the ''unfavorable'' effect of a decrease in GFR and increase in creatinine Fogari et al. reported that imidapril significantly decreased urinary albumin excretion, but there was no significant change in creatinine level up to 24 weeks in diabetic hypertensive patients with microalbuminuria (n = 88) [11] . These discrepancies between our study and these previous studies could be explained in part by differences in the duration of treatment, the study population or the study design. Our study included patients with various backgrounds and clinical settings, and used a long-term administration period up to 12 months, and the sample size was over 50 patients. Also, we used sophisticated statistical methods, including a propensity score method and a multivariable regression model to adjust background variables. On the contrary, the small sample size in these previous studies may have led to missing the true effect through the combination of reduced statistical power and increased variance. will be needed to determine the detailed effect of imidapril on renal function. However, the findings of our comparative effectiveness study, using a sophisticated statistical method in a real-world setting, are reliable and relevant to clinical practice.
CONCLUSION
In this study, we observed a greater reduction of eGFR and increase of serum creatinine and potassium levels in patients with mild to moderate hypertension who had received imidapril compared with amlodipine for at least up to 1 year. Our findings suggest that imidapril treatment slightly decreases eGFR and increases the serum levels of creatinine and potassium, and support the experience noted in clinical practice that regular checks of serum creatinine and electrolyte levels should be performed prior to and after ACEI initiation.
